Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 13Other hematologic neoplasm 8Myeloid 7CNS 4Lymphoid 2Genitourinary 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1

Conditions

Metastatic Gastrointestinal Carcinoid Tumor 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6Nivolumab 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × peginterferon alfa-2b × Endocrine × Clear all
NCT00055809 2013-01-23

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
44 enrolled
EndocrineGastrointestinal

Metastatic Gastrointestinal Carcinoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡